How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of transcutaneous electrical stimulation of the trigeminal nerve for ADHD

    Closed for comments This consultation ended on at   Request commenting lead permission

    Existing assessments of this procedure

    In 2019, the Food and Drug Administration (FDA) approved the Monarch eTNS device to treat ADHD in children aged 7 to 12 years old who are not currently taking prescription ADHD medicine (FDA press release). This approval was based on the findings of McGough, 2019 (Study 1 in this overview) and McGough, 2015 (Study 3 in this overview).